

ASX Announcement

AdAlta investor conference call audio

MELBOURNE Australia, 1 August 2018, AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to provide a link to the audio from the investor conference call from earlier today.

During the call, CEO Sam Cobb provided an update on the progress of AdAlta's lead therapeutic program for the treatment of Idiopathic Pulmonary Fibrosis, AD-214; discussed the Company's recent Placement to institutional and sophisticated investors and conducted a Q+A session, covering any questions on AD-214 progress and the Share Purchase Plan Offer, which is currently open to shareholders. To listen to the audio, please visit the following link by clicking [here](#) or on the Company website (www.adalta.com.au).

The proceeds from the Placement and the SPP will be used for manufacturing and pre-clinical studies of AD-214 as well as internal research and development of new i- bodies and corporate costs.

Under the SPP Offer, each eligible AdAlta shareholder as at 7.00pm (AEST) on 12 July 2018 (Record Time) has an opportunity to subscribe for up to \$15,000 (50,000) of new AdAlta shares. The offer price per share under the SPP Offer will be \$0.30, being the issue price under the Placement. The Offer closes at 5:00pm (AEST) on 10 August 2018.

Full details of the SPP Offer are available in the [SPP Offer booklet](#) and available on the Company's website (www.adalta.com.au).

-ENDS-

Notes to Editors
About AdAlta

AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.

We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is developing its lead i-body candidate, AD-214, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.

The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.

Further information can be found at: www.adalta.com.au.

For more information, please contact:**AdAlta Limited**

Sam Cobb, CEO

Tel: +61 (0)3 9479 5159

E: s.cobb@adalta.com.au